Trump’s GLP-1 price bargain lifts drugmakers’ volume, not patients’ savings
TL;DR Summary
STAT reports that the Trump administration’s GLP-1 price plan—$245 a month for Medicare/Medicaid, tied to insurer coverage for all uses with a $50 copay—did not consistently lower prices and instead boosted sales volume for Eli Lilly and Novo Nordisk in some cases.
- The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk statnews.com
- Medicare will start covering weight-loss drugs on July 1 for the first time. Here’s what you need to know CNN
- Medicare will begin covering weight loss drugs Wednesday. There’s a catch. NBC News
- Medicare will start covering obesity drugs for the first time. Here's what patients should know CNBC
- Medicare to cover GLP-1 treatments for weight loss WSB-TV
Reading Insights
Total Reads
1
Unique Readers
4
Time Saved
2 min
vs 3 min read
Condensed
90%
441 → 42 words
Want the full story? Read the original article
Read on statnews.com